Editorial: the immunogenicity to second anti-TNF therapy (IMSAT) therapeutic drug monitoring study-defining the risk of the in-class switch

被引：0
|
作者：
Wilson, Aze Suzanne [1 ,2 ,3 ]
机构：
[1] Western Univ, Dept Med, Div Clin Pharmacol, London, ON, Canada
[2] Western Univ, Div Gastroenterol, Dept Med, London, ON, Canada
[3] Western Univ, Dept Physiol & Pharmacol, London, ON, Canada
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2022年 / 56卷 / 08期
关键词：
INFLIXIMAB; ANTIBODIES;
D O I：
10.1111/apt.17188
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1294 / 1295
页数：2
相关论文
共 25 条
  • [21] Development and validation of a novel therapeutic drug monitoring-based nomogram for prediction of primary endoscopic response to anti-TNF therapy in active Crohn's disease
    Chen, Liang
    Kang, Dengfeng
    Fang, Leilei
    Sun, Mingming
    Li, Mingsong
    Zhou, Guangxi
    Xu, Chunjin
    Pang, Zhi
    Ye, Yulan
    Feng, Baisui
    Wu, Huili
    Lin, Jian
    Ding, Baijing
    Liu, Changqin
    Shi, Yanhong
    Liu, Zhanju
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2024, 17
  • [22] Therapeutic drug monitoring as predictive marker of mucosal healing in Crohn's disease patients treated with anti-TNF: a prospective multi-centre study
    Bertani, L.
    Bodini, G.
    Mondello, G.
    Mumolo, M. G.
    Maltinti, S.
    Baldissarro, I.
    Tapete, G.
    Albano, E.
    Ceccarelli, L.
    Crespi, M.
    Savarino, V.
    Marchi, S.
    Costa, F.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S402 - S403
  • [23] Influence of HLADQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study
    Fuentes-Valenzuela, Esteban
    Javier Garcia-Alonso, Francisco
    Maroto-Martin, Carlos
    Juan Casamayor, Laura
    Antonio Garrote, Jose
    Almendros Munoz, Rosendo
    De Prado, Angel
    Vara Castrodeza, Alejando
    Angeles Marinero, Maria
    Calleja Carbajosa, Raquel
    Barrio, Jesus
    INFLAMMATORY BOWEL DISEASES, 2023, 29 (10) : 1586 - 1593
  • [24] Advances in optimalisation of therapeutic drug monitoring using mucosal TNF expression and anti-TNF concentration in patients with inflammatory bowel disease treated with biologicals: Preliminary results from a single-centre study
    Farkas, K.
    Elekes, G.
    Kata, D.
    Foeldesi, I.
    Lada, S.
    Ferenci, T.
    Madacsy, T.
    Rutka, M.
    Balint, A.
    Bor, R.
    Fabian, A.
    Milassin, A.
    Szepes, Z.
    Nagy, F.
    Maleth, J.
    Molnar, T.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S441 - S442
  • [25] The role of bound anti-drug antibodies to infliximab in predicting future immunogenic failure when de-escalating from combination therapy with an immunomodulator to anti-TNF monotherapy: The Risk Assessment of drug-bound anti-drug-antibodies for Predicting immunogenicity during Immunomodulator De-escalation to Infliximab Monotherapy (RAPIDIM) Study
    Cameron, Karla
    Sam, Melissa
    Thennakoon, Nithya
    Gu, Bonita
    Arzivian, Arteen
    Skinner, Thomas
    Shelton, Edward
    Haifer, Craig
    Connor, Susan J.
    Toong, Catherine
    Gibson, Peter
    Gibson, David
    Boussioutas, Alex
    Sparrow, Miles P.
    Ward, Mark
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 211 - 212
123